Cardiac AmyloidosisSymptoms, Doctors, Treatments, Advances & More
Learn About Cardiac Amyloidosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cleveland Clinic Main Campus
Mazen Hanna is a Cardiologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 33 years. Dr. Hanna is rated as an Elite provider by MediFind in the treatment of Cardiac Amyloidosis. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Primary Amyloidosis, Heart Transplant, and Tenotomy.
Brigham And Women's Hospital
Rodney Falk is a Cardiologist practicing medicine in Boston,, Massachusetts. Dr. Falk is rated as an Elite provider by MediFind in the treatment of Cardiac Amyloidosis. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloidosis, Heart Transplant, and Cardiac Ablation.
Boston Medical Center Outpatient Pharmacy
Frederick Ruberg is a Cardiologist practicing medicine in Boston, Massachusetts. Dr. Ruberg is rated as an Elite provider by MediFind in the treatment of Cardiac Amyloidosis. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Heart Transplant, and Cardiac Ablation.
Summary: All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine ...
Summary: The purpose of this study is to deploy and evaluate informational AI-Echo algorithms that assist echo clinicians in interpreting core echocardiographic parameters (e.g., LV/RV size and function, valvular disease severity) and stratifying disease progression risk. The primary outcome is clinician usability, interpretive consistency, and workflow integration. Second, we will conduct a pragmatic, ste...